Addressing Inositol Use in PCOS Management
Canadian Diabetes & Endocrinology Today · 2025
DOI: 10.58931/cdet.2025.3135 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Diabetes & Endocrinology Today, 2025. Verfasst von Alyse Goldberg. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Polycystic ovary syndrome (PCOS) is a heterogeneous complex endocrine disorder characterized by oligo-ovulation, insulin resistance, and hyperandrogenism. Treatment should be individualized based on each patient’s symptoms and reproductive goals. Unfortunately, there is no pharmacologic medication that simultaneously promotes ovulation, improves metabolic health, and reduces clinical hyperandrogenism. Metformin is a well accepted, evidence-based pharmacologic therapy that targets the insulin resistance pathway and improves ovulatory frequency, but it has limited effects on clinical hyperandrogenism as well as poor tolerability for some patients. The growing interest in complementary therapies has highlighted the need for more tolerable and ‘non-pharmacologic’ treatment options. Inositol, a naturally occurring compound, has gained attention as a promising therapeutic agent for managing PCOS. This review aims to support shared decision-making between clinicians and patients by exploring the roll of inositol as a complementary therapy for PCOS management.
Zitieren
APA
Goldberg, A. (2025). Addressing Inositol Use in PCOS Management. Canadian Diabetes & Endocrinology Today. https://doi.org/10.58931/cdet.2025.3135
Vancouver
Goldberg A. Addressing Inositol Use in PCOS Management. Canadian Diabetes & Endocrinology Today. 2025. doi:10.58931/cdet.2025.3135
BibTeX
@article{Goldberg2025,
author = {Goldberg, Alyse},
title = {Addressing Inositol Use in PCOS Management},
journal = {Canadian Diabetes & Endocrinology Today},
year = {2025},
doi = {10.58931/cdet.2025.3135}
}
EUVIMED